Ghent University Academic Bibliography

Your filters: cql: author="Hodgkinson, Suzanne" or (type any "bookEditor issueEditor" and editor="Hodgkinson, Suzanne")

Add to list
Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Eva Kubala Havrdova, Tomas Kalincik, Izanne Roos, Suzanne Hodgkinson, Jeannette Lechner-Scott, et al.

(2026) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 97(1). p.50-58
Add to list
- Journal Article
- A1
- open access
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Tomas Kalincik, Sifat Sharmin, Izanne Roos, Mark S Freedman, Harold Atkins, Jennifer Massey, Ian Sutton, Barbara Withers, Joachim Burman, Øivind Torkildsen, et al.

(2026) BRAIN. 149(3). p.951-962
Add to list
- Journal Article
- A1
- open access
Managing reactivation of multiple sclerosis during treatment with natalizumab

Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Anneke van der Walt, Helmut Butzkueven, Jeannette Lechner-Scott, Katherine Buzzard, Olga Skibina, et al.

(2025) MULTIPLE SCLEROSIS JOURNAL. 32(1). p.121-133
Add to list
- Journal Article
- A1
- open access
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G. Chisari, Salvatore Lo Fermo, Alexandre Prat, Marc Girard, Pierre Duquette, Guillermo Izquierdo, et al.

(2025) NEUROTHERAPEUTICS. 22(2).
Add to list
- Journal Article
- A1
- open access
Four years on : pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, Sara Eichau, Stella Hughes, Barbara Willekens, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Cavit Boz, et al.

(2025) MULTIPLE SCLEROSIS JOURNAL. 31(9). p.1088-1101
Add to list
Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Dana Horakova, Bianca Weinstock-Guttman, Vahid Shaygannejad, Masoud Etemadifar, Raed Alroughani, et al.

(2025) JAMA NEUROLOGY. 82(6). p.614-625
Add to list
- Journal Article
- A1
- open access
Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Jessica Shipley, Heidi N. Beadnall, Paul G. Sanfilippo, Wei Zhen Yeh, Dana Horakova, Eva Kubala Havrdova, Pavel Hradilek, Tomas Kalincik, Izanne Roos, Alexandre Prat, et al.

(2025) JAMA NETWORK OPEN. 8(9).
Add to list
- Journal Article
- A1
- open access
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Izanne Roos, Sifat Sharmin, Charles Malpas, Serkan Ozakbas, Jeannette Lechner-Scott, Suzanne Hodgkinson, Raed Alroughani, Sara Eichau Madueño, Cavit Boz, Anneke van der Walt, et al.

(2024) MULTIPLE SCLEROSIS JOURNAL. 30(9). p.1163-1175
Add to list
- Journal Article
- A1
- open access
Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies

Wei Z. Yeh, Anneke Van Der Walt, Olga G. Skibina, Tomas Kalincik, Raed Alroughani, Allan G. Kermode, Marzena J. Fabis-Pedrini, William M. Carroll, Jeannette Lechner-Scott, Cavit Boz, et al.

(2024) NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 11(6).
Add to list
- Journal Article
- A1
- open access
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Anoushka P. Lal, Yi Chao Foong, Paul G. Sanfilippo, Tim Spelman, Louise Rath, David Levitz, Marzena Fabis-Pedrini, Matteo Foschi, Mario Habek, Tomas Kalincik, et al.

(2024) JOURNAL OF NEUROLOGY. 271. p.5813-5824

Academic Bibliography

Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

Managing reactivation of multiple sclerosis during treatment with natalizumab

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Four years on : pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability

Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Contents

Support

Contact